Four biotech stocks are lighting up the IBD 50 with high Relative Strength Ratings. One is near a buy point.
Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged.
At this time, I would like to welcome everyone to the Harmony Biosciences second quarter 2022 financial update conference call. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences second quarter 2022 financial performance and provide a business update. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.